Marinho Rui T, Vitor Sofia, Velosa Jose
Department of Gastroenterology and Hepatology Hospital Santa Maria Medical School of Lisbon,Lisbon, Portugal.
Department of Gastroenterology and Hepatology Hospital Santa Maria Medical School of Lisbon, Lisbon, Portugal.
J Gastrointestin Liver Dis. 2014 Mar;23(1):85-90.
The hepatitis C virus (HCV) infection is one of the most important chronic viral infections worldwide and affects 3% of the world population, approximately 170-200 million people. The consequences of chronic infection are liver cirrhosis and hepatocellular carcinoma, which develop in 20-30% of the patients, leading to hepatic failure, need for liver transplantation and death. The hepatitis C virus is a RNA virus that is prevalent worldwide and is classified by the World Health Organization (International Agency for Research on Cancer) as one of the six oncogenic viruses. Hepatocellular carcinoma is one of the most important cancers and is fifth worldwide, but third in men in terms of mortality. Hepatitis C kills approximately 350,000 people every year, surpassing HIV infection in many countries as a cause of death. Hepatitis C virus can kill in different ways: it can cause cirrhosis, cancer or severe liver disease in people co-infected with HIV. Hepatitis C treatment started in the mid 1980s with a 6% efficacy rate among patients taking thrice-weekly injections of human interferon. This therapy had numerous side effects. The efficacy of hepatitis C treatment has increased, and currently, the efficacy of the so-called direct antiviral agents (DAAs) is 80-90%. The benefits of a cure are enormous and include a lifetime negative serum HCV RNA, disappearance of HCV in the liver, regression of cirrhosis, decreased risk of developing hepatocellular carcinoma, disappearance of oesophageal varices, no more risk of HCV transmission to sexual partners or children, and increased survival. At present, hepatitis C can be considered a curable disease.
丙型肝炎病毒(HCV)感染是全球最重要的慢性病毒感染之一,影响着全球3%的人口,约1.7亿至2亿人。慢性感染的后果是肝硬化和肝细胞癌,20%至30%的患者会发展成这些疾病,导致肝衰竭、需要进行肝移植以及死亡。丙型肝炎病毒是一种RNA病毒,在全球广泛流行,被世界卫生组织(国际癌症研究机构)列为六种致癌病毒之一。肝细胞癌是最重要的癌症之一,在全球排名第五,但在男性死亡率方面排名第三。丙型肝炎每年导致约35万人死亡,在许多国家作为死因超过了艾滋病毒感染。丙型肝炎病毒可以通过不同方式致人死亡:它可在合并感染艾滋病毒的人群中引发肝硬化、癌症或严重肝病。丙型肝炎治疗始于20世纪80年代中期,接受每周三次注射人干扰素治疗的患者有效率为6%。这种疗法有许多副作用。丙型肝炎治疗的疗效有所提高,目前,所谓的直接抗病毒药物(DAAs)的有效率为80%至90%。治愈的益处巨大,包括终身血清HCV RNA呈阴性、肝脏中HCV消失、肝硬化消退、肝细胞癌发生风险降低、食管静脉曲张消失、不再有将HCV传播给性伴侣或儿童的风险以及生存率提高。目前,丙型肝炎可被视为一种可治愈的疾病。